Floatz logo

Entrectinib

KRAS G12C Mutation

Alliance for Clinical Trials in OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the KRAS G12C Mutation cohort.

Asset / SponsorPhaseRating
Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2B
ibi351
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
PANITUMUMAB
Federation Francophone de Cancerologie Digestive
Phase 2CCC
Fulzerasib
Jianxing He
Phase 2CCC
Paxalisib
Alliance for Clinical Trials in Oncology
Phase 2CCC

View all 12 →

Same molecule, other indications

Entrectinib is also rated in:

hematopoietic and lymphoid system neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Anatomic Stage IV Breast Cancer AJCC v8Dormant
B
Indicative ·
62 / 100
View asset →
sarcomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →